✦ LIBER ✦

Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows

✍ Scribed by Rena Buckstein; Karen Jang; Jessica Friedlich; Liying Zhang; Marciano Reis; Alden Chesney; Richard A. Wells

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 228 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.02.010

No coin nor oath required. For personal study only.

✦ Synopsis

Although unexplained anemia is common in the elderly, the prevalence of MDS is poorly defined. We reviewed 2267 bone marrows reviewed at our center between the years 2002 and 2005. Of these, 322 met our criteria for inclusion (14%). Seventy-three patients (22.6%) had a confirmed diagnosis of MDS and 32 (9.9%) had suspected MDS. Confirmed or suspected MDS was more likely in patients aged >65 (31.5% and 11%, respectively). Age, MCV, LDH and RDW were independently predictive of MDS. Extrapolation of our findings to the elderly anemic individuals in the community suggests MDS prevalence may be higher than previously postulated.

📜 SIMILAR VOLUMES

DNA content of granulocytes, monocytes,

DNA content of granulocytes, monocytes, and lymphocytes in the bone marrow smears of patients with myelodysplastic syndromes

✍ Susanne Widell; Robert Hast; Christopher Cox; Gert Auer; John M. Bennett 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

The clinical significance of activated l

The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients

✍ Stef Meers; Peter Vandenberghe; Marc Boogaerts; Gregor Verhoef; Michel Delforge 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 457 KB

We studied the immune compartment in patients with myelodysplastic syndromes. We show increased surface expression of activation markers (HLA-DR(+), CD57(+), CD28(-), CD62L(-)) on T lymphocytes in blood and bone marrow (n=131). T cell activation was not restricted to any relevant clinical subgroup (

Successful rapid discontinuation of immu

Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome

✍ Kazushi Tamura; Takashi Kanazawa; Michiko Suzuki; Mikiko Koitabashi; Chitose Oga 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

Characteristics of novel myeloid precurs

Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome

✍ Gordana Bogdanović; Vladimir Jurišić; Nada Kraguljac; Jasminka Mrdjanović; Dimit 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 659 KB

We report on characteristics of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome (t-MDS) who had no overt post-MDS leukemia. Classic cytology analyses, immunophenotyping, cytogenetic and molecular genetic procedures were used fo

Azacitidine for the treatment of lower r

Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program

✍ Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

## Abstract ## BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high‐risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have

The prognostic significance of bone marr

The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome

✍ Di Lu; Randa Nounou; Miloslav Beran; Elihu Estey; Taghi Manshouri; Hagop Kantarj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract ## BACKGROUND It has been reported that point mutations of the ras gene occur frequently in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the prognostic significance of ras gene mutations in patients with these disorders has been a controversial issue. Altho